No link between COVID-19 vaccines & sudden deaths: ICMR-AIIMS Study

​Union Minister of Health and Family Welfare said that extensive studies by the Indian Council of Medical Research (ICMR) and All India Institute of Medical Sciences have conclusively established no linkage between COVID-19 vaccines and sudden deaths among adults post-COVID-19.

The Ministry noted that studies conducted by ICMR and the National Centre for Disease Control (NCDC) affirm that COVID-19 vaccines in India are safe and effective, with extremely rare instances of serious side effects. The incidence of sudden cardiac deaths can result from a wide range of factors, including genetics, lifestyle, pre-existing conditions, and post-COVID complications. The ICMR and NCDC have been working together to understand the causes behind sudden, unexplained deaths, especially in young adults between the ages of 18 and 45 years.

Akashvani correspondent reports that to explore this, two complementary studies were undertaken using different research approaches-one based on past data and another involving real-time investigation. The findings of the first study have conclusively shown that COVID-19 vaccination does not increase the risk of unexplained sudden death in young adults. The second study is currently being conducted by AIIMS, New Delhi.

Early analysis indicates that heart attacks, or myocardial infarction, continue to be the leading cause of sudden death in this age group. The studies offer a more comprehensive understanding of sudden unexplained deaths in young adults in India. They also reveal that COVID-19 vaccination does not appear to increase the risk, whereas the role of underlying health issues, genetic predisposition and risky lifestyle choices does play a role in unexplained sudden deaths. Scientific experts have reiterated that statements linking COVID vaccination to sudden deaths are false and misleading, not supported by scientific consensus.

Related Posts

Rajasthan Bans 7 Sub-Standard Medicines

Prioritising public health and patient safety, the Commissionerate of Food Safety and Drug Control, Rajasthan, has issued an alert regarding seven medicines and declared them “Not of Standard Quality”. Prioritising…

ONESOURCE’s partner receives USFDA tentative approval for Semaglutide Injection

OneSource Speciality Pharma announced that its partner Orbicular Pharmaceutical Technologies (Orbicular), together with its U.S.-based front-end partner (the ANDA holder), has secured tentative U.S. Food and Drug Administration (FDA) approval…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

NCB Hyderabad raids illegal lab, seizes 69 kg of Alprazolam worth Rs 17.4 crore

NCB Hyderabad raids illegal lab, seizes 69 kg of Alprazolam worth Rs 17.4 crore

Rajasthan Bans 7 Sub-Standard Medicines

Rajasthan Bans 7 Sub-Standard Medicines

ONESOURCE’s partner receives USFDA tentative approval for Semaglutide Injection

ONESOURCE’s partner receives USFDA tentative approval for Semaglutide Injection

Ajanta Pharma gets USFDA Form 483 with five observations at Paithan plant

Ajanta Pharma gets USFDA Form 483 with five observations at Paithan plant

Obesity drug market to gain as Indians pop the pill and Chinese bring more

Obesity drug market to gain as Indians pop the pill and Chinese bring more

Aurobindo Pharma Rs 800 Cr Buyback Opens Apr 23

Aurobindo Pharma Rs 800 Cr Buyback Opens Apr 23